Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Atazanavir
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 11, 2022
Lead Product(s) : Atazanavir
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atazanavir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Fiocruz Investigates the Action of Anti-Retrovirals Against Covid-19
Details : Fiocruz research observed that the drug Atazanavir was able to inhibit viral replication and to reduce the production of proteins that are related to the inflammatory process in the lungs in COVID-19.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 04, 2020
Lead Product(s) : Atazanavir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atazanavir
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 10, 2020
Lead Product(s) : Atazanavir
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atazanavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Fundació Clínic per a la Recerca Biomèdica
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 12, 2016
Lead Product(s) : Atazanavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Fundació Clínic per a la Recerca Biomèdica
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atazanavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
SSAT067 PK of Atazanavir/Cobicistat and Darunavir/Cobicistat
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 28, 2015
Lead Product(s) : Atazanavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atazanavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Bristol Myers Squibb | ViiV Healthcare
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of a Nucleoside Sparing Regimen in HIV-1 Infected Patients With Detectable Viremia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 07, 2015
Lead Product(s) : Atazanavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Bristol Myers Squibb | ViiV Healthcare
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atazanavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : INSERM UMR S1136
Deal Size : Inapplicable
Deal Type : Inapplicable
Study Evaluating the Efficacy of a Reduced Dose Atazanavir in HIV-1-infected Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 16, 2015
Lead Product(s) : Atazanavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : INSERM UMR S1136
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atazanavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Taste Properties of Atazanavir and Cobicistat
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 04, 2014
Lead Product(s) : Atazanavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atazanavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 14, 2014
Lead Product(s) : Atazanavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atazanavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 20, 2013
Lead Product(s) : Atazanavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable